managing toxicity post-car-t therapy in multiple myeloma
Published 2 years ago • 132 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
2:10
managing hematologic toxicity associated with car-t therapy & insights into the car-hematotox score
-
3:06
management of multiple myeloma during car-t therapy manufacturing
-
4:12
car-t therapy in multiple myeloma: recent updates, clinical trials and future outlooks
-
1:12
optimizing car-t therapy for patients with multiple myeloma in the real-world
-
2:57
strategies to optimize car-t therapy in myeloma: bringing car-t into earlier lines
-
18:33
car t-cell therapy: reprogramming the immune system to treat cancer | rob weinkove | tedxtauranga
-
11:18
car-t cells: engineered cancer killers
-
9:59
can knowing your mrd status help guide treatment?
-
4:04
overcoming challenges in car t-cell therapy for multiple myeloma
-
1:38
real world use of car t-cell therapy in multiple myeloma
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
3:57
mechanisms and management of short- and long-term car-t toxicities
-
2:30
the management of car-t related toxicities in leukemia and lymphoma
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
3:27
car-t cells in myeloma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
2:06
the optimal sequencing of car-t and other immunotherapies in multiple myeloma
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all
-
1:56
identifying and managing patients at high risk of developing toxicities following car-t therapy
-
1:44
managing car t-cell therapy toxicities within treatment centres